Zymeworks BC Inc (NASDAQ: ZYME) on Monday, soared 29.05% from the previous trading day, before settling in for the closing price of $18.52. Within the past 52 weeks, ZYME’s price has moved between $9.03 and $20.17.
Annual sales at Healthcare sector company grew by 15.81% over the past five years. The company achieved an average annual earnings per share of 37.51%. With a float of $72.81 million, this company’s outstanding shares have now reached $75.14 million.
Zymeworks BC Inc (ZYME) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Zymeworks BC Inc is 3.45%, while institutional ownership is 99.27%. The most recent insider transaction that took place on May 15 ’25, was worth 565,847. In this transaction Director of this company bought 49,502 shares at a rate of $11.43, taking the stock ownership to the 17,877,989 shares. Before that another transaction happened on May 19 ’25, when Company’s Director bought 5,919 for $11.78, making the entire transaction worth $69,738. This insider now owns 17,883,908 shares in total.
Zymeworks BC Inc (ZYME) Latest Financial update
As on 12/31/2024, Multinational firm has announced its last quarter scores, in which it reported -0.31 earnings per share (EPS) for the period falling under the consensus outlook (set at -0.09) by -0.22. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.09 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 37.51% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 21.33% during the next five years compared to 15.81% growth over the previous five years of trading.
Zymeworks BC Inc (NASDAQ: ZYME) Trading Performance Indicators
Zymeworks BC Inc (ZYME) is currently performing well based on its current performance indicators. A quick ratio of 6.94 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 13.40.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.85, a number that is poised to hit -0.49 in the next quarter and is forecasted to reach -0.63 in one year’s time.
Technical Analysis of Zymeworks BC Inc (ZYME)
Zymeworks BC Inc (NASDAQ: ZYME) saw its 5-day average volume 3.23 million, a positive change from its year-to-date volume of 0.64 million. As of the previous 9 days, the stock’s Stochastic %D was 65.95%.
During the past 100 days, Zymeworks BC Inc’s (ZYME) raw stochastic average was set at 84.40%, which indicates a significant increase from 77.52% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 1.09 in the past 14 days, which was higher than the 0.69 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $17.57, while its 200-day Moving Average is $14.03. Nevertheless, the first resistance level for the watch stands at $25.88 in the near term. At $27.85, the stock is likely to face the second major resistance level. The third major resistance level sits at $29.51. If the price goes on to break the first support level at $22.24, it is likely to go to the next support level at $20.58. The third support level lies at $18.60 if the price breaches the second support level.
Zymeworks BC Inc (NASDAQ: ZYME) Key Stats
Market capitalization of the company is 1.80 billion based on 74,837K outstanding shares. Right now, sales total 76,300 K and income totals -122,700 K. The company made 27,610 K in profit during its latest quarter, and -19,600 K in sales during its previous quarter.
